SNG Stock Overview
Synairgen plc discovers and develops drugs for respiratory diseases.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Synairgen plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.051 |
52 Week High | UK£0.17 |
52 Week Low | UK£0.04 |
Beta | -2.29 |
1 Month Change | 1.35% |
3 Month Change | -14.73% |
1 Year Change | -36.29% |
3 Year Change | -96.78% |
5 Year Change | -59.24% |
Change since IPO | -96.72% |
Recent News & Updates
Here's Why We're Not Too Worried About Synairgen's (LON:SNG) Cash Burn Situation
Dec 09Here's Why We're Watching Synairgen's (LON:SNG) Cash Burn Situation
Aug 24Recent updates
Here's Why We're Not Too Worried About Synairgen's (LON:SNG) Cash Burn Situation
Dec 09Here's Why We're Watching Synairgen's (LON:SNG) Cash Burn Situation
Aug 24Is Synairgen (LON:SNG) In A Good Position To Invest In Growth?
Apr 29Companies Like Synairgen (LON:SNG) Could Be Quite Risky
Dec 27We're A Little Worried About Synairgen's (LON:SNG) Cash Burn Rate
Sep 13Companies Like Synairgen (LON:SNG) Could Be Quite Risky
May 31Here's Why We're Not Too Worried About Synairgen's (LON:SNG) Cash Burn Situation
Feb 06We're Hopeful That Synairgen (LON:SNG) Will Use Its Cash Wisely
Oct 21We're Hopeful That Synairgen (LON:SNG) Will Use Its Cash Wisely
Mar 29How Much Of Synairgen plc (LON:SNG) Do Institutions Own?
Dec 14Shareholder Returns
SNG | GB Biotechs | GB Market | |
---|---|---|---|
7D | 2.0% | -1.6% | 0.9% |
1Y | -36.3% | -28.9% | 2.2% |
Return vs Industry: SNG underperformed the UK Biotechs industry which returned -27.3% over the past year.
Return vs Market: SNG underperformed the UK Market which returned 2.7% over the past year.
Price Volatility
SNG volatility | |
---|---|
SNG Average Weekly Movement | 8.9% |
Biotechs Industry Average Movement | 7.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.1% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: SNG's share price has been volatile over the past 3 months.
Volatility Over Time: SNG's weekly volatility has decreased from 15% to 9% over the past year, but is still higher than 75% of UK stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | 34 | Richard Marsden | https://www.synairgen.com |
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease. The company was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Synairgen plc Fundamentals Summary
SNG fundamental statistics | |
---|---|
Market cap | UK£10.26m |
Earnings (TTM) | -UK£9.99m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.0x
P/E RatioIs SNG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SNG income statement (TTM) | |
---|---|
Revenue | UK£0 |
Cost of Revenue | UK£0 |
Gross Profit | UK£0 |
Other Expenses | UK£9.99m |
Earnings | -UK£9.99m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.05 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did SNG perform over the long term?
See historical performance and comparison